Answers are grounded in this paper and cite their sources.
A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.
No takes yet. Share an insight, caveat, or question.
Rebold et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: